Earnings Call: Q3 2026

Nov 2, 2026

Summary

Q3 revenue grew 14.5% and Adjusted EBITDA rose 32.4%, alongside 19.5% U.S. procedure-volume growth. Onyx alpha launch, new Granite DRGs, and broader physician adoption support expected Q4 growth above 20%; FY 2026 revenue guidance was reaffirmed.

Good afternoon, and welcome to SI-BONE's third quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Saqib Iqbal, Vice President, FP&A and Investor Relations at SI-BONE, for a few introductory comments. Earlier today, SI-BONE released financial results for the quarter ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management's remarks today may include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, such as our most recent Form 10-K and Form 10-Q, and actual results may differ materially from any forward-looking statements that we make today. Accordingly, you should not place undue reliance on these statements. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. During the call, management may also discuss certain non-GAAP measures, including Adjusted EBITDA and free cash flow. Unless otherwise noted, any reference to profitability is in terms of positive Adjusted EBITDA. For a reconciliation of these non-GAAP measures to GAAP accounting, please see the company's full earnings release issued earlier today. Unless otherwise noted, all results are compared to the comparable period in the prior year. With that, I'll turn the call over to Laura. Thanks, Saqib. Good afternoon, and thank you for joining us. We delivered a solid third quarter with accelerating procedure demand, broader physician adoption, and improving financial performance. These results reflect disciplined execution of our multi-year strategy to expand our differentiated platform into new clinical applications. By focusing on anatomy-specific solutions that enable durable fixation and fusion in patients with compromised bone, we're reaching more patients and expanding our growth opportunity. Worldwide revenue grew approximately 15% to $55.7 million. U.S. revenue increased approximately 14% to $52.8 million. U.S. procedure volume increased approximately 20%, supported by 16% growth in active physicians. The strong double-digit volume growth across all procedure types demonstrates that our targeted platform expansion and call point diversification strategies are delivering. In addition to the strong surge in demand in the third quarter, demand accelerated for our expanded INTRA platform from interventional spine physicians in the office-based and ASC sites of care. Our decision to build differentiated solutions with applications across all sites of care has made INTRA the preferred platform for this call point. International revenue grew 27% to $2.9 million, supported by continued adoption of technologies launched in the last 12 months. We converted the revenue growth into stronger financial performance. Adjusted EBITDA increased 32%, more than twice the pace of revenue growth, while working capital discipline contributed to stronger operating cash flow. Innovation remains a key component of our long-term growth as we develop differentiated technologies to improve procedural outcomes for high-risk patients with compromised bone quality. We pioneered minimally invasive treatment for SI joint dysfunction, then applied that experience to develop Breakthrough Devices targeting sacroiliac fixation in complex fusion, as well as pelvic fragility fractures. With the recent launch of iFuse Granite Onyx, we're now taking that proven expertise in developing anatomy-specific solutions beyond the pelvis. Onyx received FDA 510(k) clearance in September, and it's our third product to receive FDA Breakthrough Device designation. We believe Onyx, which is designed to address the known failure points at the upper and lower ends of the spine fusion construct, represents one of the most significant product launches in our history. The addition of Onyx increases our estimated total addressable market to over 650,000 procedures, representing an annual total market opportunity of approximately $5 billion. Onyx is the first of several differentiated technologies that we plan to bring to market that address significant unmet clinical needs, and where our expertise in compromised bone gives us a clear advantage. We initiated the alpha launch of Onyx in October and are extremely pleased with the surge in interest. Early demand is tracking ahead of Granite over the comparable launch period. While we expect a modest contribution in the fourth quarter, as we move to full launch, we see Onyx as a meaningful accelerant to long-term growth. Recent reimbursement enhancements have added another long-term growth catalyst. New DRGs for multi-level spinal fusion procedures that incorporate pelvic fixation with Granite took effect October 1st. Depending on patient diagnosis and severity, the increase in the average hospital payment could be up to $50,000 per qualifying procedure. We believe the reimbursement framework will enable physicians and patients to access our Granite platform, further extending our leadership in the nearly $1 billion target market, and allowing us to potentially provide additional solutions, such as Onyx, in these same procedures. Together, these developments mark a defining moment for SI-BONE. We're substantially expanding our addressable market, the new DRGs have created a more favorable reimbursement environment, and we have a highly engaged physician base, all of which give us confidence in delivering durable long-term growth. That confidence is also implied in our 2026 guidance, which at the midpoint would imply over 20% revenue growth in the fourth quarter. I will now discuss our three key growth drivers: innovation and market development, physician engagement, and commercial execution. Anshul will then cover our fourth priority, operational excellence, inside of financial results and outlook. Starting with innovation and market development. As the U.S. population ages and lives longer, osteoporosis and osteopenia are becoming more prevalent. This creates a growing need for advanced technologies that enable durable fixation and fusion in compromised bone. We believe our biomechanical expertise in developing anatomy-specific technology gives us a competitive advantage that is difficult to replicate. Our Granite and Onyx platforms are clear examples of our disruptive innovation targeting known failures in complex fusions. Granite was our first major platform targeting failures in complex fusion, starting at the base of spinal fusion procedures. In the last four years, we believe Granite has become the standard of care in sacropelvic fixation. Onyx expands our complex fusion platform by addressing screw loosening at the upper and the lower instrumented vertebra, another major challenge in spinal fusion. Published literature reports screw loosening in as many as 27% of spinal fusion constructs, with higher risks in patients with osteoporosis. We've done this before. In the randomized SILVIA trial, adding fixation across the SI joint alongside S2AI screws reduced new-onset SI joint pain from 8.5% to 1.1% following deformity surgery. With Granite, the PAULA study showed a 3.3% pelvic fixation failure rate at 12 months, compared to a 23.7% failure rate at two years reported for traditional pelvic screws in large deformity databases. With Onyx, we're bringing that same osteointegrative approach with the goal of delivering similar results. Onyx is one of the most technologically advanced solutions we've developed. We believe the anatomy-specific thread design and implant stiffness tailored to varying vertebral bone density promotes early fixation, which is crucial to reducing implant loosening and also facilitates long-term bone integration. We estimate the market for Onyx at approximately 200,000 annual U.S. procedures, representing a market opportunity of approximately $1.5 billion. Combined with Granite, our total market opportunity in complex fusion now stands at approximately $2.5 billion. Onyx will also benefit from our substantial commercial footprint and large presence in complex fusion procedures. When Granite launched in 2022, we had over 700 active physicians, and we were in the early stages of building out our third-party agent network. Today, we have approximately 1,770 active physicians and over 300 agents. In the first few weeks of the alpha launch, Onyx is already generating incremental procedures within our existing accounts, while higher implant utilization is increasing overall procedure average selling price. As more surgical capacity comes online, we're confident that this commercial reach will accelerate Onyx adoption. From a reimbursement standpoint, depending on the number of levels fused and additional technologies being used, the new DRGs I highlighted earlier may also benefit Onyx, especially in qualifying long spinal fusion cases. Additionally, as a Breakthrough Device designated device, Onyx is eligible for the alternative pathway for a new technology add-on payment, or NTAP. We've submitted our application to CMS, and if approved, the NTAP would take effect on October 1st, 2027. In SI joint dysfunction, our largest market for minimally invasive surgical procedures, our actions to broaden our portfolio and expand physician call points to also include interventional spine physicians are delivering results. Our comprehensive portfolio serves both call points across all sites of service and extends our reach to a broader subset of patients. In the third quarter, surgeons accounted for the vast majority of procedures, but adoption of the INTRA platform among interventional spine physicians was a significant contributor to procedure growth. We believe INTRA has established a leading position in SI joint fusion among interventional physicians, supported by our comprehensive portfolio, clinical evidence, and training programs. Proposed CMS reimbursement changes could also strengthen demand for our solutions in this market. Under the proposal, hospital outpatient and ASC payments would increase to more than $20,000 and $16,000 respectively, and new office payments of $20,000 per CPT 27279 would be established. If finalized, these changes would take effect January 1, 2027, improve procedure economics, and expand patient access. We expect CMS to issue the final ruling in the coming days. In trauma, we continue to collaborate with Smith+Nephew on surgeon awareness and education to treat sacral insufficiency fractures using iFuse TORQ TNT. As we enter the busy season for trauma, our joint commercial actions over the last six months are starting to deliver, as we're seeing growing adoption of our platform. Looking ahead, we're advancing several programs targeting large established markets with significant unmet needs and high procedure failure rates. These solutions apply our compromised bone expertise to new clinical challenges and build on existing physician relationships and commercial infrastructure. By organizing our innovation around the needs of these high-risk patients, we remain committed to improving procedural outcomes. Now, turning to physician engagement, we ended the quarter with approximately 1,770 active physicians, representing 16% year-over-year growth. We're proud of our double-digit physician growth in every quarter for nearly six years, which we attribute to the impact of our innovation that is improving patient outcomes, the quality of our targeting activity, as well as the prudent investment in physician education and high-quality clinical research. Given our sizable installed base, we're also focused on deeper physician engagement to increase the number of cases per physician. While we continue to see steady increases in the number of physicians performing multiple procedure types, Onyx has the potential to materially accelerate this trend. Even in this limited launch period, Onyx is already driving an increase in the number of cases, as well as the increase in the number of products used per case among existing Granite physicians. Next, let's turn to commercial execution. We ended the third quarter with 93 quota-carrying territory managers. Our trailing 12-month average revenue per territory was $2.2 million, representing 7% improvement. These productivity gains reflect the operating leverage in a hybrid model strategy, as our direct team focuses on physician education and relationships, while third-party agents extend procedural coverage and market reach. We're targeting to exit 2026 with nearly 100 territories. The added field capacity will allow us to capture the anticipated Onyx demand, deepen physician engagement, capitalize on the interventional momentum, and prepare for future launches. Before I hand it over to Anshul, I want to thank our colleagues for their dedication and execution. I especially want to recognize our teams involved in the development and launch of Onyx. I also want to compliment our market access team, whose work helped secure the new Granite DRGs. Onyx marks the beginning of our next wave of innovation, and I'm excited about what we can accomplish. We're helping physicians treat thousands of patients and improve their quality of life. Now, Anshul will discuss our financial results and outlook for the rest of the year. Thanks, Laura. Good afternoon, everyone. Our third quarter results demonstrate our ability to drive strong procedure growth, improve profitability, and generate operating cash while investing in future opportunities. Let me provide additional details on our financial performance. Starting with revenue growth. Worldwide revenue was $55.7 million, representing 14.5% growth. U.S. revenue increased 13.9% to $52.8 million, driven by 19.5% procedure volume growth, partially offset by lower average selling price. The robust volume in a seasonally slower quarter for the industry reflects the benefits of our strategy to build a diversified portfolio serving both surgeons and interventional pain physicians. With nearly 650,000 annual target procedures that can benefit from our highly differentiated technologies, we believe we are in the early stages of accelerating procedure volume growth. The ASP was impacted by procedure mix, which drives the average number of implants per case, as well as the site of care mix, as our INTRA platform adoption increased in faster-growing ASC and in-office settings, which typically carry lower ASP. International revenue increased 27% to $2.9 million, driven by growing TORQ and TNT procedure volume. Turning to profitability. Gross profit increased 13.7% to $44.2 million. Gross margin was 79.3%, continuing to track ahead of guidance. The minimal change in gross margin reflects the site of care and procedure mix I highlighted earlier, partially offset by the improving surgical capacity utilization and implementation of production workflow changes to reduce implant costs as well as optimize instrument costs. Operating expenses increased 9.7%, well below revenue growth of 14.5%, demonstrating our ability to scale efficiently. Higher spending reflected sales commissions, marketing activities to support new products, and continued R&D investment. Based on the trends through the first three quarters, we believe 2026 operating leverage will be better than our expectations at the beginning of the year. Net loss narrowed to $3.6 million, or $0.08 per diluted share, compared to a net loss of $4.6 million, or $0.11 per diluted share. Adjusted EBITDA increased 32.4% to $3 million, representing an Adjusted EBITDA margin of 5.5%. Over the trailing 12 months, our Adjusted EBITDA increased approximately 140% to nearly $13.6 million, and Adjusted EBITDA margin more than doubled. Going forward, we expect strong revenue growth and continuing operating leverage to drive further margin expansion and move us towards GAAP profitability. Turning to liquidity and cash flow. Our working capital discipline and asset-light operating model are converting improved operating performance into cash. We ended the quarter with $146.3 million in cash and equivalents, up approximately $400,000 sequentially. Year to date, we generated approximately $4.4 million in operating cash flow, compared with $2.4 million used in the prior year period, an improvement of $6.8 million. Our robust balance sheet and progress towards consistent free cash flow generation positions us to fund our planned development programs while maintaining significant financial flexibility. Turning to 2026 outlook. We are reaffirming our 2026 worldwide revenue of $231 million-$233 million, as well as our gross margin expectations at 79%. While we are making growth-oriented investments related to Onyx launch and ongoing R&D projects, based on the year-to-date performance, we now expect our operating expenses to grow 10.5% versus our prior expectation of 12%. The midpoint of our annual worldwide revenue guidance implies over 20% year-over-year revenue growth in the fourth quarter. As we enter our seasonally strongest quarter, our fourth quarter growth acceleration is anchored by the strengthening and broad-based procedure demand, a growing base of active physician, an expanded commercial footprint, and modest contribution from new products. The new Granite DRGs and a broader rollout of Onyx offers additional growth potential, both in terms of volume and procedure ASP upside. Early indications from these catalysts in October reinforce our confidence in a strong finish to 2026 and significant operating momentum entering 2027. With that, I will turn the call over to Laura. Thanks, Anshul. We are entering our next phase of growth with a differentiated portfolio, deeper physician engagement, and a more favorable reimbursement environment. We have built the commercial scale to capture these opportunities, and our results demonstrate the operating leverage that growth can deliver. Looking ahead, we are very confident in our ability to accelerate growth, improve profitability, and help more patients achieve better outcomes. With that, we are happy to answer your questions. Operator? Thank you. If you would like to ask a question, please press star 11 on your telephone. You will then hear an automated message advising your hand is raised. If you would like to remove yourself, press star 1 again. We also ask that you wait for your name and company to be announced before proceeding with your question. One moment while we compile the Q&A roster. Our first question will be coming from the line of Patrick Wood of UBS. Please go ahead. Beautiful. Thanks so much for taking the questions, guys. Just two up front. First one on Onyx. Obviously, in alpha launch at the moment, but I would love any extra color you guys have from the clinician and surgeon feedback, and if you are going to change anything as you go into full release, anything you are going to tweak, just feedback there would be great. Then secondly, big picture, you mentioned several times, obviously, accelerating procedure growth. Q4, the implied guide is for a nice acceleration. How much is Onyx going to keep that momentum as we move through into next year, even before the NTAP actually comes online? Thanks. seeing is the answer is yes to that question. That's number one. Number two, wanted to see is physicians that are using Onyx, are they using Onyx when they don't go to the pelvis, where they typically don't use Granite? The answer is yes to that as well. Then finally, we want to see if non-users of Granite are wanting to use Onyx, and the answer is yes to that question too. We're really excited by what we're seeing here just in the last 30 days or so. They're early trends, and all of the things that we talked about in terms of increasing procedure volumes and seeing implant utilization per case increase with Onyx is happening in the early stages. Also what gives us a lot of encouragement is Granite has been a huge success for us, and when we compare the demand for Onyx to the early demand for Granite, it's actually tracking ahead of where Granite was as well. Maybe not that surprising because we've built such a strong number of physicians who are using our technologies. Once again, as I said in pre-prepared remarks, we had around 700 physicians that were active when we launched Granite, and now we're at almost 1,800, right? Also, just the footprint that we have in the U.S. as well with the larger number of territory managers and territory reps, but also our third-party agents as well. I think all of those things are really important. The excitement is really evident with our commercial team. We have actually quite a bit of inbound demand already for Onyx. For us, it's really deploying additional surgical capacity out there in November and December, and then we expect the full launch in January. Then, Patrick, on the guidance side, you're correct. The midpoint of our full year guidance implies a 20% revenue growth in the fourth quarter. The acceleration that we expect to see in the fourth quarter is actually a buildup of all the activities we engaged in throughout the year. It started with the meaningful physician-based growth that we've seen. Just comparing third quarter to third quarter, we've added nearly 250 additional physicians. The expansion to interventional, as Laura said in her prepared remarks, is actually doing well. The INTRA platform is really accelerating adoption within the interventional space, and we saw that happen in the third quarter, which tends to be a slow quarter generally, so that bodes well for the fourth quarter. The last piece would be on the trauma side. We've been working very closely with Smith+Nephew to sort of build the foundations entering a busy trauma quarter as well, and coming into the fourth quarter, we're seeing the benefit of that as well. The last piece on Onyx, what's incorporated in the guidance. When we started the year, we had said Onyx would be available at some point late in the fourth quarter. We're obviously ahead of track on that, given that Onyx was in alpha launch in October. The color Laura provided, it's actually doing quite well for us. I think net-net, we're positioned really well. The two things that could provide potentially additional upside would be the impact of new DRGs on Granite, especially as we think about the third quarter, we had more Granite cases with two implants. As we continue to drive awareness in the DRGs, can we move that to four? As we continue to broaden our alpha launch with more surgical sets out there for Onyx, could that be additional upside for us as well? I think we feel very good about the setup ending the year, and then also what it sets us up as we look out the next few years from a growth perspective. No, Tara. Thanks so much, guys. Thank you. One moment for the next question. The next question will be coming from the line of Matthew O'Brien from Piper Sandler. Please go ahead. Good afternoon. Thanks for taking the questions. Maybe just to keep going on Onyx for a second here. Laura, you mentioned the 1,800 active docs roughly that you have now. How quickly can you access those clinicians? It would seem like that is the low-hanging fruit versus going after people that had not been working with you in the past. Is there any kind of metric we should think about in terms of how many you can get to by the middle of next year, by the end of next year? Anything along those lines? Then just talk a little bit about training, how quickly they can get up the curve in terms of getting accustomed to Onyx and being able to incorporate it in their practice, and then I do have a follow-up. Yeah. Thanks, Matt. Good questions. In terms of Onyx, you are right. This first quarter is really focused primarily on just the alpha launch that we are working on right now. As we continue with every single week, we are pushing out more trays into the field as well as more inventory as well. Given just the sheer number of surgeons that are already using our Granite product, it gives us the opportunity to work with them, first of all, in these Granite cases themselves, right? We actually have an opportunity to have a significant throughput and increase the revenue per case with adding Onyx just into existing Granite cases. Then also, you have these 1,800 active physicians as well at the same time, and a lot of those physicians. They are doing cases that don't necessarily go to the pelvis, and so they haven't been using Granite in those cases, but they are going to be more likely to use Onyx either at the top of the construct or at the bottom of the construct. So, for example, in cases where surgeons use both Granite and Onyx, we are seeing utilization of around 6 implants per procedure, which is going to translate to that increase in the revenue per case that I just mentioned. In addition to all of that, there is also the opportunity to go after new surgeons too that had not, for one reason or another, adopted the Granite technology, and we are already starting to see cases with some of these key opinion leader surgeons in the early stages that are interested in our Onyx product. I think your question on the commercial infrastructure being in place, and it is really just expanding the surgical capacity is what is really going to be important. You also talked about training a little bit, and the training is very straightforward, very similar to what we did with Granite. We do a similar sort of a tray review with the surgeon before a case. They are already used to using other technologies in these cases, so it is just a reminder of here is our solution, here are our instruments, and so the adoption and the road to training these surgeons is a very quick one. The only other thing I would add, Matt, there is, Onyx is a line extension. So from a VAC committee approval perspective, it is actually a very seamless process for us. It is just targeting a different disease state, like Laura said, of the UIV and LIV. Okay. Appreciate that. Something in the press release really got my attention. It is talking about setting you guys up for the strongest foundation for growth acceleration in the history of the company. I mean, you have done 20%, 30% growth in the past. I am not expecting the high end of that 30% number next year, but the street settled in at about 15.5% growth for next year on the top line. That would seem to be well below what you can likely do given all the tailwinds. Is that a fair assessment, or is there something else that we should be contemplating? Thanks so much. Yeah. So Matt, I can take that question. When we make that comment, and we do not make it lightly, if you look at the structural multi-year tailwinds that we have in our business, I will just summarize the top six that we have. The expanded call point strategy with interventional spine is translating into faster penetration in the SI joint dysfunction market. The proposed expanded coverage for site of care that may be announced any day at this point, assuming it is finalized, could be a further tailwind in that business for us. The Smith & Nephew collaboration is starting to gain some momentum as well. We have talked about the new DRGs, the impact it can have on Granite adoption and more implants per case. Onyx, again, we are in alpha launch right now. We are going to put more capacity out in 2027 throughout the year into 2028. Then you have got the potential benefit of NTAP at the end of 2027 as well. Then we have got other projects we are working on. So, truly a lot of tailwinds in the business. Now, as excited as we are about those tailwinds, we are still in the early stages of evaluating their impact, and we feel good about the growth prospects into 2027, but we want to get a few more months behind us from a performance standpoint before we talk about 2027. Our focus is on closing the year strong, go through our planning process, which we are under right now, then talk about guidance and expectations in late February when we announce our fourth quarter earnings. Look, we are going to consistently be thoughtful and prudent in our approach, but we do believe that these tailwinds are not just limited to 2027, but even beyond. Great. Thanks so much. Thank you. One moment for the next question. Our next question is coming from the line of Richard Newitter of Truist Securities. Please go ahead. Hi. Thanks for taking the questions. Maybe just to follow on Matt's question just now. On the bottom line, I was just wondering if you could offer any thoughts as you potentially are about to move into one of the biggest acceleration or most confident points of jump-off points for acceleration going forward, and on profitability, what that could look like. It looks like you are on track to potentially exit at around 9% in 2026, Justin, Adjusted EBITDA margin. That is about what you did exiting last year, 4Q 2025. Just curious how we should think about the ramp, especially with what seem like pretty significant drivers, both from a margin standpoint and just sheer growth dollars. Then I have a follow-up. Yeah. No, Richard, happy to take that question. Our profitability is an outcome of our strong top-line growth. Let's just start with that. As a result, we've reflected a reduction in OPEX growth for the year. When we think about the coming years from a profitability standpoint, we do have a lot of growth-oriented investments that we want to be able to make in the business. We do remain committed to our operating leverage expectations. As we've always said, on the low end, it's 1.25 times revenue growth to OPEX growth, and could be as high as 1.75 times over the long term. These investments we think are really important to continue to drive this sustained long-term growth that we'd like to see the business deliver. It's around investment in R&D personnel and our own machining capabilities to support the annual cadence of new product launches. We do expect to expand our sales force to capture the demand that we're seeing across all the call points. As we launch new products, including Onyx, we want to make sure we are investing in training and marketing activities. These are deliberate investments that we want to be able to make in the business to drive growth, but we do expect that the accelerating top-line growth should allow us to drop a significant amount of dollars to the bottom line, even at the midpoint of the leverage being around 1.4, 1.5 times. Thanks. Maybe just one follow-up. Look, congratulations. Really nice acceleration in your procedure growth this quarter. But the ASP took a little step back. I guess maybe anything to call out there, Anshul or Laura? Yeah. How should we think of that trend in the 4Q, especially if you've got increased revenue procedure tailwinds? That's a great question, Richard. So again, 20% procedure volume growth in the third quarter. It's actually very encouraging. We're very pleased with that, especially when you think about all the noise around slowdown in procedure volumes. From an ASP standpoint, when we started the year, we had talked about sort of low to mid-single-digit ASP degradation from a per-procedure standpoint, especially as the mix evolves. Now, when you think about the reach of our platform today, it now ranges from single implant procedures where INTRA is used in an ASC or in an office setting on one end, and on the other end, you've got cases with Granite and also now Onyx, which could be 4-plus implant cases, which are performed in inpatient settings. So, both of these factors can have an impact on our ASP. When we looked at the third quarter, what we saw was Granite continued to grow well, but we did see an increase in 2-implant Granite cases, which generally tend to be more on the Degen side versus the 4-implant side. Now, with the new DRG changes, we're continuing to educate people on the benefits of two points of fixation on either side. Then the strong demand on INTRA from interventional spine physicians in the ASC and office-based setting, which typically carries a lower ASP, was expected. But what was encouraging was it's actually allowing us to penetrate the huge multi-billion dollar untapped SIJD TAM we've been targeting for so long. So, as we think about our ASP, two most important variables will be around where the volume growth is coming from and the site of service. Laura talked a little bit about it earlier in the comments. Even in the early stages of Onyx, what we are seeing is the average procedure ASP is actually moving up coming into the fourth quarter, because we're starting to see some of the benefits of Onyx and also the uptake in multi-implant Granite cases go higher. Now, offsetting that is going to be the interventional volume, but we think net-net, you should see an improvement in ASP in the fourth quarter given the dynamics, the way they're playing out. Thank you. Thank you. One moment for the next question. Our question will be coming from Caitlin Roberts of Canaccord Genuity. Please go ahead. Hi. Thanks so much for taking the questions. Maybe just jumping off of, Anshul, what you mentioned about the procedure volume growth, which was strong, obviously given the noise that you've heard from others. Maybe just a little bit more color on what you are seeing as it relates to procedure volume just across your call points. Yeah. Thanks, Caitlin, for the question. I mean, if you look at the third quarter with the volume growth at 20%, we would say the short answer is no, that we're not seeing this concern that you're hearing from some other companies. Now, it may be that we're just in a unique position in the industry. We're targeting unmet clinical needs and known failures in various fusion procedures, and it's clearly resonating with our customers. I think also the fact that we're building new TAMs, and now we're at a point where we're targeting over 600,000 annual procedures. We're not fighting for market share gains. We're more identifying these new opportunities, and that's contributing to the growth that we're seeing. I can't necessarily speculate on the macro impact and the broader industry volumes, but just given our particular situation with multiple growth drivers, we think we're really well-positioned to navigate if there are headwinds or issues that are out there and to drive strong growth. Even coming into the fourth quarter, if you look at our guidance, it's saying that our best estimate is that we will exceed 20% growth. What we're seeing and expecting is continued strong demand across the portfolio, and especially given the tailwinds with Onyx and then the new Granite DRGs, and finally, the interventional ramp as well, it bodes well for us. Great. Then just on the Smith+Nephew partnership, any KPIs in terms of surgeon or facility penetration you could share? Just thoughts on maybe partnering with them or another company for any future products that don't necessarily fit your core call points. Yeah, thanks for asking about that. Actually, we're making nice progress with Smith+Nephew at this point. It does usually take some time in order to build that relationship and to see the results, especially in the case of SI-BONE, we're a pretty nimble company that is able to innovate and bring products to market and see the impact fairly quickly. But working with a larger company, it does tend to take a little bit more time. But over the last several months, we've been focused on surgeon education training and also just expanding access to TNT at these various trauma centers. There is this normal onboarding period with physician engagement, hospital approvals, and the initial procedures. But we're pleased with what we're seeing exiting Q3 and entering Q4, which is typically more of a seasonally stronger period for trauma. We are starting to see the results of our joint commercial efforts. Great. Thank you. Thank you. One moment for the next question. Next question's coming from the line of Young Li of Jefferies. Please go ahead. All right, great. Thanks for taking the question. I guess maybe back to Onyx. Wanted to hear, I guess, a little bit more on the attachment rate for Onyx with the classic Granite cases. I guess, what are you seeing in the alpha launch group so far? How frequently are they being used together versus not? Where do you think that can go longer term? Yeah. I mean, I talked a little bit about some of the measures that we're currently using. As you're stating, the most obvious application is for our surgeons to use Onyx in the same cases as Granite, and we're seeing that come through. It's low-hanging fruit, as you well, if you look at that opportunity. What's also happening is, let's talk about the surgeons that are using Granite regularly when they go to the pelvis. What we're seeing is that those surgeons are actually using Onyx in the cases where they're not going to the pelvis. So, they may not be using Granite in those cases, but they are surgeons that have been using our products for an extended period of time, and now really like what we're offering here with Onyx for their patients with compromised bone. As I mentioned, the issue is really having issues with screw loosening in these patients that have compromised bone. So the application is well understood, and there's an excitement with our surgeons that we're finally solving this problem overall. Then finally, we're actually seeing surgeons who have not used Granite previously, but they actually are interested in using Onyx. As you said, I would say the primary use case is in those surgeons that we've been working with for an extended period of time, in many cases, in those procedures where they're using Granite, but we're seeing much more than that as well. I did talk a little bit about implant utilization as well in these cases, where what we're seeing in a case where they're typically using Granite and Onyx together is they're using six implants in those cases. It's a pretty exciting opportunity, and it just gives us this significant benefit in terms of increasing surgeon density that we didn't necessarily have with our portfolio previously. Young, the thing I would say is, if you even look at the underlying TAM, Granite's underlying TAM is about 130,000 cases, 140,000 cases, of which about 30,000 to 40,000 cases were in the adult deformity space. Given the complexity of those adult deformity procedures, our expectation is almost all those cases where you use Granite, you might want to use Onyx at the top and the bottom of the construct. That's what's embedded in our TAM numbers. Then once you get beyond that, within the degen space, when you think about the number of fusion procedures that happen there's around 400,000 procedures. Our best estimate is 100,000 of those end at the sacrum, and that's where Granite would have been used. UIV LIV can extend beyond those 100,000 cases as well, especially when you think about the number of those patients that have osteoporosis. Rough estimate, one in three patients, and if you look at patients who are over 50, even more patients have osteoporosis, and Onyx would have application there at the UIV and LIV as well, and those end up around 150,000 cases. Now, those are bread-and-butter cases too for a lot of physicians that may not do Granite, because they may not be at academic centers, but do do SI joint dysfunction. So we've got a nice overlap of physicians that can use Onyx whether they use Granite or not. All right, great. That's very helpful. I guess, wanted to follow up a little bit on that concept. I guess, what are your expectations for any potential halo effects from Onyx, where you can enable some conversion or pull through of surgeons to the other products in your portfolio? I think there is no question that there is a halo effect. I talked a little bit about the clinical data that we have on our Granite technology. We recently had a surgeon that came into a board meeting that just talked about the fact that we have really addressed the issue at the bottom of the long construct with Granite. Now we are proving it out with our SILVIA study information and then also our PAULA study information too. It is well known that you have this issue with the upper part of the spine and the lower part of the spine. In these particular cases with Onyx, it is another major failure point at the top and the bottom of the spine. Published literature is actually reporting screw loosening in as many as 27% of spinal fusion constructs. There is this understanding of what the problem actually is. There is also an understanding that SI-BONE was able to address the issue at the bottom of the long construct. Now we are moving to the next area that is a significant challenge for these particular surgeons and their patients. I am going to go back to what you said in terms of a halo effect. I do believe that all the work that we have done on Granite does have a halo effect, and that it will have an impact on Onyx sales. All right. Thank you. Thank you. One moment, please, for the next question. Our question is coming from the line of Grecia Mahoney of Bank of America. Please go ahead. Hey. Thanks for taking the questions. The first one I wanted to ask on was just in the prepared remarks, you talked about how the new DRGs may benefit Onyx. Just wanted to clarify if they already map to it today. If not, what needs to happen for that to occur? Maybe just in terms of an NTAP strategy, if you do that, what sort of the application filing timeline process would be like, and what you're doing to prepare hospitals for reimbursement around the product? Yeah. No, good questions, Grecia. We are excited about the new Granite DRGs. We've been working for an extended period of time with CMS on this particular topic, and we're really pleased that they created these new DRGs, recognizing the clinical complexity and the additional costs associated with treating these patients. From a Granite perspective, these new DRGs went into place on October 1st of 2026, so it's going to have an impact on the Granite business. If you think about where we were previously, the NTAP expired October 1st of 2025. For the last 12 months, there has not been a Granite NTAP in place. Now with these new DRGs, and these new DRGs, if you look at the reimbursement, they pay up to an additional $50,000 more for qualifying cases. It does provide the opportunity for hospitals and surgeons to feel confident in using Granite. If you think about the NTAP, the NTAP is specific to Medicare cases, whereas the new DRGs are going to cover all payers, not just Medicare, but also commercial payers too. We think that all of that is really important just for our Granite business. Now, you asked about the impact on Onyx as well, and as I said, a lot of the cases that we're seeing currently with Onyx are being done in conjunction with Granite. Those cases are going to be accessing the new higher-paying DRGs. In terms of cost, the new DRGs are helping to address the higher cost associated with these technologies. You also asked about the NTAP for Onyx. We have already applied for an NTAP with CMS, and given that this is a Breakthrough Device, we should be able to follow an alternative pathway with our Onyx technology, and we'll know for sure October 1st of 2027. Earlier than that, I think April already, we'll get some information on the NTAP for Onyx specifically. We do think that there's another opportunity there for Onyx in the future with the NTAP, but also currently in conjunction with Granite cases. Okay. Super helpful. Thank you. How to think about maybe all these product launches and any incremental impact to gross margin. I think Street's modeling gross margin down a little bit versus this year, so any sort of puts and takes to consider there as we go into 2027? Yeah, I think it's a good question, and I'll have Anshul talk a little bit about the gross margin impact. The question about additional product launches is an important one. We really are looking at a compromised bone opportunity here, and what it's done is it's created this opportunity to significantly expand our product roadmap, and for us to be regularly putting out product in order to meet these new opportunities and address them. Very similar to what we've done already with Granite, for example, with pelvic fixation, very similar to what we've done with TNT, with pelvic trauma, and now finally with Onyx, with the top and the bottom of the spine construct. We have more opportunities to further expand and regularly launch products. I'll let Anshul talk about the gross margin impact. Yeah. Thanks for that question. We really feel great about our industry-leading gross margins. Year to date, we've actually tracked ahead of what we guided, and part of that is just our focus on asset utilization and implant and tray cost reduction initiatives. As our business scales with that strong top-line growth, we are focused on driving more incremental revenue dollars to the bottom line and progressing towards improving GAAP profit dollars now. When you think about 2027, and I'll provide a couple years expectations there, going into 2027, we do anticipate some modest gross margin pressure. Most of that is from the higher non-cash depreciation expenses associated with the additional Onyx surgical capacity we plan to deploy, and to support the procedure demand that we expect from Onyx. As Laura said earlier, beyond Onyx, we do expect to bring additional platforms to market in the next few years, which we know will meaningfully accelerate top-line growth given how differentiated they are and they're going after known unmet needs. As we launch these technologies, we've talked about it historically that we expect gross margin to be in sort of that 78% area as you go beyond 2027. Most of that's going to be driven by the subscale nature of the new products and higher non-cash costs from tray depreciation. What that does not include is our expectations to work on cost reduction initiatives with our manufacturing partners on our existing portfolio, as well as our internal operational efficiency efforts, which include driving high utilization through setting up loaner operations, and things like that. Again, very focused on gross margin profitability. We think even at that 78%, 79%, it will be industry-leading, and that should translate well into operating profit at the adjusted level and also GAAP profitability in the not-too-distant future. Thank you. One moment, please, for the next question. Our next question is coming from the line of Matt Blackman of Cowen. Please go ahead. Good afternoon, everybody. Can you hear me okay? Yes. Great. Thank you for taking my question. I am just going to leave it to one. Laura, shockingly, the question will be on Onyx. I am curious, some of the early feedback we have been hearing from clinicians is focused on them wanting to see some commercial, clinical, and economic outcomes data before putting Onyx into their armamentarium. That does not strike me as an unusual request with a new product, but just curious what you are hearing from physicians, and to the extent you do need to build, we will call it a commercial data dossier, what is the pathway to do that? How big do you think that needs to be? How long out do you think that data needs to be? Any color on that would be helpful. Thank you. Yeah. As you know, we're very used to putting together high-quality clinical data. We have almost 200 peer-reviewed published papers, including four randomized controlled trials and many more prospective studies as well. The approach that we're taking here is very similar to what we did with our Granite technology. We have bench data, and then we have all of the information on the high rate of failure at the upper and lower ends of the long spinal constructs. In a lot of these cases, these surgeons actually don't have a good alternative solution. What we're seeing is, given how well we handled the situation with Granite and addressed the issue at the bottom of the long construct, and the quality of the bench data and the product itself and the osteointegrative nature of the product, it already is lending itself to surgeons that are interested in using the product now. What we're doing is we're working with those particular surgeons. With that said, we're also looking at the opportunity to build that additional clinical data. In terms of how we're thinking about Onyx, what we're doing is we're leveraging the benchtop and animal studies that we have currently. It's compared to conventional screws. It compares very well to those. We're also going to launch a prospective multicenter clinical study to evaluate Onyx safety and clinical performance as well. Very similar to what we've done in the past. Finally, one of the other ways that surgeons do address these issues in patients is they use bone cement along with pedicle screws. But in these particular cases, cement, it can improve initial fixation, but it comes with trade-offs. The cement can leak outside the vertebra. You can have the potential for nerve injury, pulmonary embolisms, creates a rigid interface that doesn't integrate with bone. Then it can even raise the risk of fractures at the adjacent level. The alternatives that surgeons have right now, they're not good alternatives. Getting back to your question, I do think that there are going to be the early adopter surgeons that understand that there are no good solutions for these patients right now. Then there are going to be others that are going to wait. In terms of the amount of time that they'll look, typically 6-12 months, they're going to want to see some information that shows how these particular patients did. But typically, we'll run our clinical data out at least 2 years, if not 5 years. I hope that's helpful. Great. Thank you. Very helpful. Thank you. Thank you. One moment for the next question. Our next question is coming from the line of David Saxon of Needham & Company. Please go ahead. Great. Good afternoon. Thanks for taking my question, Laura and Anshul. I'll keep it to one as well. Just wanted to follow up on the revenue per case commentary. I mean, it sounds like you'll start to see a benefit from Onyx here in the fourth quarter. Just given how early it is in the launch, and I guess that's going to offset what you're seeing with INTRA, is it fair to expect some pricing tailwind, or revenue per case tailwind as we go into 2027? Just any color there would be helpful. Thanks so much. Yeah. I mean, I'll talk about 2027, David, once we close out the fourth quarter on a strong note, get through our planning, and come on the other side. Historically, we've always assumed coming into the new year some ASP degradation again because the portfolio mix evolving. What you've got in our story right now is you've got an exciting opportunity with an interventional with SI joint dysfunction, where we are becoming the market leader in that space with the most comprehensive solution set. Reimbursement changes there could be another tailwind, assuming CPT 27279 gets approved for office-based or in-office procedures. You got that on one side, which will be a big volume driver. On the flip side, you've got Granite and Onyx with the new DRGs, but also the symbiotic nature of these products being used together in the same procedure. You should get a tailwind from that. So, I think net-net, we will talk about more on the ASP assumptions when you get into 2027, but all indications are you have got the volume benefit on both sides with Granite, Onyx, and interventional, but you will have additional ASP upside from Onyx Granite. Great. Thanks so much. Thank you. One moment for the next question. Our next question is coming from the line of Daniel Stauder of Citizens. Please go ahead. Yeah, great. Thanks for taking the questions. I will try to keep it to one as well. Just thinking about operating expenses, I appreciate you giving those op leverage bands as we think about 2027 and beyond, but I think you mentioned that you expect to expand the sales force as well to try to keep up with some of this demand. First, how much of an investment could that be? Is it fair to assume that they will be mostly focused on Onyx and Bedrock? Then, how should we think about any cadence in terms of spend in 2027 with the potential rep adds and any incremental spend as you get the Onyx launch going? Thank you. Yeah. Happy to take that question, Dan. When we think about our operating leverage in the business, like I've always shared, it's driven by top-line growth, and our profitability performance reflects that inherent operating leverage that we've built. Now, with a lot of the untapped opportunities that we see ahead of ourselves, both with the existing portfolio as well as new product launches, we do think the investments we want to make, whether it's on the R&D clinical side, like Laura talked about on the Onyx clinical side, we believe is really important to continue to drive penetration and adoption there. In terms of the expansion of the sales force, we're going to be very thoughtful. The reason to expand the sales force is going to be because we see specific markets where there are huge opportunities, whether it's with an interventional or whether it's with Granite, Onyx, to be able to drive growth there or in the SI joint fusion business as well. We're not going to sacrifice productivity at the sales per territory. As we expand, we're going to be very thoughtful about it, and that's what gives us confidence in the continued operating leverage in the business of, on the low end, the 1.25 times, on the high end, the 1.75 times, which should translate into expanded profitable dollars falling to the bottom line. No, it's really helpful. Thank you very much. Thank you. That concludes today's Q&A session. I would like to turn the call back to Laura for closing remarks. Please go ahead. I just wanted to say thank you to everyone for participating in today's call, and we also really appreciate your interest in SI-BONE. Finally, we look forward to seeing you all at upcoming conferences as well as non-deal roadshows. Thanks again. Goodbye. This concludes today's programming. Thank you so much for joining. You may now disconnect.